Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Alessandra Fabi; Diana Giannarelli; Luca Moscetti; Daniele Santini; Alberto Zambelli; Michelino De Laurentiis; Michele Caruso; Daniele Generali; Enrichetta Valle; Vita Leonardi; Katia Cannita; Grazia Arpino; Gianfranco Filippelli; Gianluigi Ferretti; Marianna Giampaglia; Filippo Montemurro; Cecilia Nisticò; Simona Gasparro; Francesco Cognetti

doi:10.2217/fon-2017-0336

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Alessandra Fabi, Diana Giannarelli, Luca Moscetti, Daniele Santini, Alberto Zambelli, Michelino De Laurentiis, Michele Caruso, Daniele Generali, Enrichetta Valle, Vita Leonardi, Katia Cannita, Grazia Arpino, Gianfranco Filippelli, Gianluigi Ferretti, Marianna Giampaglia, Filippo Montemurro, Cecilia Nisticò, Simona Gasparro, Francesco Cognetti

Istituto Regina Elena

Research output: Contribution to journal › Article

Abstract

AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen.

PATIENTS & METHODS: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73).

RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01).

CONCLUSION: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.

Original language	English
Pages (from-to)	2791-2797
Number of pages	7
Journal	Future Oncology
Volume	13
Issue number	30
DOIs	https://doi.org/10.2217/fon-2017-0336
Publication status	Published - Dec 2017

Fingerprint

Keywords

Journal Article

Cite this

Fabi, A., Giannarelli, D., Moscetti, L., Santini, D., Zambelli, A., Laurentiis, M. D., Caruso, M., Generali, D., Valle, E., Leonardi, V., Cannita, K., Arpino, G., Filippelli, G., Ferretti, G., Giampaglia, M., Montemurro, F., Nisticò, C., Gasparro, S., & Cognetti, F. (2017). Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter? Future Oncology, 13(30), 2791-2797. https://doi.org/10.2217/fon-2017-0336

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients : does pretreatment with pertuzumab matter? / Fabi, Alessandra ; Giannarelli, Diana; Moscetti, Luca; Santini, Daniele; Zambelli, Alberto; Laurentiis, Michelino De; Caruso, Michele; Generali, Daniele; Valle, Enrichetta; Leonardi, Vita; Cannita, Katia; Arpino, Grazia; Filippelli, Gianfranco; Ferretti, Gianluigi; Giampaglia, Marianna; Montemurro, Filippo; Nisticò, Cecilia; Gasparro, Simona; Cognetti, Francesco.

In: Future Oncology, Vol. 13, No. 30, 12.2017, p. 2791-2797.

Research output: Contribution to journal › Article

Fabi, A , Giannarelli, D, Moscetti, L, Santini, D, Zambelli, A, Laurentiis, MD, Caruso, M, Generali, D, Valle, E, Leonardi, V, Cannita, K, Arpino, G, Filippelli, G, Ferretti, G, Giampaglia, M, Montemurro, F, Nisticò, C, Gasparro, S & Cognetti, F 2017, 'Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?', Future Oncology, vol. 13, no. 30, pp. 2791-2797. https://doi.org/10.2217/fon-2017-0336

Fabi, Alessandra ; Giannarelli, Diana ; Moscetti, Luca ; Santini, Daniele ; Zambelli, Alberto ; Laurentiis, Michelino De ; Caruso, Michele ; Generali, Daniele ; Valle, Enrichetta ; Leonardi, Vita ; Cannita, Katia ; Arpino, Grazia ; Filippelli, Gianfranco ; Ferretti, Gianluigi ; Giampaglia, Marianna ; Montemurro, Filippo ; Nisticò, Cecilia ; Gasparro, Simona ; Cognetti, Francesco. / Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients : does pretreatment with pertuzumab matter?. In: Future Oncology. 2017 ; Vol. 13, No. 30. pp. 2791-2797.

@article{6e353705ac2c43748da86d267962cf6b,

title = "Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?",

abstract = "AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen.PATIENTS & METHODS: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73).RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01).CONCLUSION: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.",

keywords = "Journal Article",

author = "Alessandra Fabi and Diana Giannarelli and Luca Moscetti and Daniele Santini and Alberto Zambelli and Laurentiis, {Michelino De} and Michele Caruso and Daniele Generali and Enrichetta Valle and Vita Leonardi and Katia Cannita and Grazia Arpino and Gianfranco Filippelli and Gianluigi Ferretti and Marianna Giampaglia and Filippo Montemurro and Cecilia Nistic{\`o} and Simona Gasparro and Francesco Cognetti",

year = "2017",

month = dec

doi = "10.2217/fon-2017-0336",

language = "English",

volume = "13",

pages = "2791--2797",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "30",

}

TY - JOUR

T1 - Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients

T2 - does pretreatment with pertuzumab matter?

AU - Fabi, Alessandra

AU - Giannarelli, Diana

AU - Moscetti, Luca

AU - Santini, Daniele

AU - Zambelli, Alberto

AU - Laurentiis, Michelino De

AU - Caruso, Michele

AU - Generali, Daniele

AU - Valle, Enrichetta

AU - Leonardi, Vita

AU - Cannita, Katia

AU - Arpino, Grazia

AU - Filippelli, Gianfranco

AU - Ferretti, Gianluigi

AU - Giampaglia, Marianna

AU - Montemurro, Filippo

AU - Nisticò, Cecilia

AU - Gasparro, Simona

AU - Cognetti, Francesco

PY - 2017/12

Y1 - 2017/12

N2 - AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen.PATIENTS & METHODS: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73).RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01).CONCLUSION: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.

AB - AIM: We evaluated the outcomes of patients treated with ado-trastuzumab emantasine (T-DM1) after first-line pertuzumab/trastuzumab, compared with those receiving a trastuzumab-only-based regimen.PATIENTS & METHODS: Patients who received second-line T-DM1 after pertuzumab/trastuzumab (n = 34) were compared with those who received only trastuzumab (n = 73).RESULTS: Overall response rate was 33.3% in patients with prior pertuzumab and 57.1% in the remaining subjects. Disease control rate was 47 and 43%, respectively, and the clinical benefit rate was 43.3 and 71.1%, respectively. Median progression-free survival was 5.0 and 11.0 months, respectively (hazard ratio: 2.02; 95% CI: 1.14-3.58; p = 0.01).CONCLUSION: Patients treated with T-DM1 who previously received pertuzumab present poorer clinical outcomes compared with those receiving a trastuzumab-only-based regimen in the first-line setting.

KW - Journal Article

U2 - 10.2217/fon-2017-0336

DO - 10.2217/fon-2017-0336

M3 - Article

C2 - 29182361

VL - 13

SP - 2791

EP - 2797

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 30

ER -

Access to Document

10.2217/fon-2017-0336